Abstract

These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.

Keywords

PCSK9MedicineInternal medicineCardiologyHazard ratioMyocardial infarctionCholesterolEvolocumabIncidence (geometry)Confidence intervalPopulationAlirocumabEndocrinologyLipoproteinLDL receptorApolipoprotein A1

Affiliated Institutions

Related Publications

Publication Info

Year
2006
Type
article
Volume
354
Issue
12
Pages
1264-1272
Citations
3106
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

3106
OpenAlex

Cite This

Jonathan C. Cohen, Eric Boerwinkle, Thomas H. Mosley et al. (2006). Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease. New England Journal of Medicine , 354 (12) , 1264-1272. https://doi.org/10.1056/nejmoa054013

Identifiers

DOI
10.1056/nejmoa054013